Anadis is a biotechnology company based in Melbourne, Australia that trades on the Australian Stock Exchange with the symbol IMC. an ADR Level I program was initiated in late 2007, and the company is quoted over the counter in the U.S. with the ticker ANDIY
The company focused on antigen-primed, dairy-derived health products. Immuron’ proprietary, technology enables it to rapidly develop polyclonal antibody and other proteins-based solutions to a range of important diseases.
Immuron specialises in nutraceutical, pharmaceutical and related therapeutic technology products, including Oral and GI Mucositis, Routine and Avian Influenza, - E. coli Travellers' diarrhoea (TD), Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), and Anthrax containment.